GSK’s Zejula is the only oral monotherapy available as a first-line maintenance treatment for women regardless of BRCA mutational status, addressing a high unmet need in ovarian cancer.
As it moves into its second century in business, Upsher-Smith Labs is focusing on innovating and growing its product offerings while maintaining its high standards.